Trials / Completed
CompletedNCT00319917
A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients
FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the efficacy on joint damage and safety in RA patients treated with DMARDs in a double blind, placebo controlled study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tacrolimus | oral |
| DRUG | placebo | oral |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2006-04-27
- Last updated
- 2014-08-21
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00319917. Inclusion in this directory is not an endorsement.